309 related articles for article (PubMed ID: 26494411)
1. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH; Halvorsen TO; Fløtten Ø; Brustugun OT; Brunsvig PF; Aasebø U; Bremnes RM; Tollåli T; Hornslien K; Aksnessæther BY; Liaaen ED; Sundstrøm S;
Acta Oncol; 2016 May; 55(5):591-7. PubMed ID: 26494411
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Lung Cancer; 2022 Apr; 166():49-57. PubMed ID: 35183991
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.
Suzuki R; Wei X; Allen PK; Welsh JW; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2018 Nov; 19(6):e885-e891. PubMed ID: 30197263
[TBL] [Abstract][Full Text] [Related]
4. Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.
Viani GA; Gouveia AG; Matsuura FK; Jacinto AA; Moraes FY
Radiother Oncol; 2022 Aug; 173():41-48. PubMed ID: 35101470
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
Halvorsen TO; Sundstrøm S; Fløtten Ø; Brustugun OT; Brunsvig P; Aasebø U; Bremnes RM; Kaasa S; Grønberg BH
Acta Oncol; 2016 Nov; 55(11):1349-1354. PubMed ID: 27549509
[TBL] [Abstract][Full Text] [Related]
6. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
7. Thoracic Radiotherapy in Limited-Stage SCLC-a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018.
Graabak G; Grønberg BH; Sandvei MS; Nilssen Y; Halvorsen TO
JTO Clin Res Rep; 2022 Feb; 3(2):100270. PubMed ID: 35146461
[TBL] [Abstract][Full Text] [Related]
8. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
[TBL] [Abstract][Full Text] [Related]
9. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH; Killingberg KT; Fløtten Ø; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
Lancet Oncol; 2021 Mar; 22(3):321-331. PubMed ID: 33662285
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
[TBL] [Abstract][Full Text] [Related]
11. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
15. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
16. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717
[TBL] [Abstract][Full Text] [Related]
17. Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies.
Hu X; Xia B; Bao Y; Xu YJ; Wang J; Ma HL; Peng F; Jin Y; Fang M; Tang HR; Chen MY; Dong BQ; Jin JN; Fu XL; Chen M
Strahlenther Onkol; 2020 Feb; 196(2):172-181. PubMed ID: 31784801
[TBL] [Abstract][Full Text] [Related]
18. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
[TBL] [Abstract][Full Text] [Related]
19. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]